Jan 9, 2023 4:05pm EST Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Jan 4, 2023 8:00am EST Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference